Simcere Pharmaceutical Group Ltd

2096.HK

$0.72

Closing

▼-3.93%

1D

▼-16.49%

YTD

Market cap

$1.88B

52 week high

$1.08

52 week low

$0.63

Volume

8,657,830

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$1.88B

Analysts' Rating

BUY

Price Target (Mean)

0.00

Total Analysts

0

P/E

19.44

Operating Margin

0.00%

Beta

0.35

Revenue Growth (Annual)

-

52 week high

$1.08

52 week low

$0.63

Div. Yield

2.97%

EPS Annual Growth

0.00

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Simcere Pharmaceutical Group Ltd is a company engaged in research and development, production and sales of drugs. The Company’s main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The Company also produces innovative drugs, such as Endostar used for oncology. The Company is also involved in providing promotion services for third-party drugs sold by medical institutions.